We previously showed that, in vitro, hyperforin from St. John's wort (Hypericum perforatum) inhibits 5-lipoxygenase (5-LO), the key enzyme in leukotriene biosynthesis. Here, we demonstrate that hyperforin possesses a novel and unique molecular pharmacological profile as a 5-LO inhibitor with remarkable efficacy in vivo. Hyperforin (4 mg/kg, i.p.) significantly suppressed leukotriene B(4) formation in pleural exudates of carrageenan-treated rats associated with potent anti-inflammatory effectiveness. Inhibition of 5-LO by hyperforin, but not by the iron-ligand type 5-LO inhibitor BWA4C or the nonredox-type inhibitor ZM230487, was abolished in the presence of phosphatidylcholine and strongly reduced by mutation (W13A-W75A-W102A) of the 5-LO C2-like domain. Moreover, hyperforin impaired the interaction of 5-LO with coactosin-like protein and abrogated 5-LO nuclear membrane translocation in ionomycin-stimulated neutrophils, processes that are typically mediated via the regulatory 5-LO C2-like domain. Together, hyperforin is a novel type of 5-LO inhibitor apparently acting by interference with the C2-like domain, with high effectiveness in vivo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11115900 | PMC |
| http://dx.doi.org/10.1007/s00018-009-0078-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A quality by design strategy for cocrystal design based on novel computational and experimental screening strategies: part A.
Drug Deliv Transl Res
November 2024
Centre for Research Innovation (CRI), University of Greenwich, Medway Campus, Chatham Maritime, Kent, ME4 4TB, UK.
While pharmaceutical Cocrystals have long been acknowledged as a promising method of enhancing a drugs bioavailability, they have not yet experienced widespread industrial adoption on the same scale as other multi-component drugs, such as salts and amorphous solid dispersions. This is partly due to the lack of a being no definitive screening strategy to identify suitable coformers, with the most cocrystal screening strategies heavily relying on trial and error approaches, or through utilizing a multiple and often conflicting, computational screening techniques combined with high material consumption experimental techniques. From the perspective of industry, this can often lead to high material waste and increased costs, encouraging the prioritization of more traditional bioenhancement techniques.
View Article and Find Full Text PDFUnlocking the potential: unveiling tyrphostins with Michael-reactive cyanoacrylate motif as promising inhibitors of human 5-lipoxygenase.
Pflugers Arch
December 2024
Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438, Frankfurt Am Main, Germany.
Article Synopsis
- Human 5-lipoxygenase (5-LO) is an important enzyme that helps produce substances called leukotrienes, which are involved in the immune response and can cause inflammation and cancer.
- Researchers found new chemical compounds that effectively block 5-LO, particularly focusing on a family of inhibitors called tyrphostins.
- Two specific compounds, degrasyn and AG556, were identified as strong 5-LO blockers that work by attaching to parts of the enzyme, which could lead to new treatments for inflammatory diseases and cancer.
Inhibition of host 5-lipoxygenase reduces overexuberant inflammatory responses and mortality associated with meningoencephalitis.
mBio
September 2024
Department of Biology, Texas Christian University, Fort Worth, Texas, USA.
Unlabelled: Cryptococcosis, caused by fungi of the genus , manifests in a broad range of clinical presentations, including severe pneumonia and disease of the central nervous system (CNS) and other tissues (bone and skin). Immune deficiency or development of overexuberant inflammatory responses can result in increased susceptibility or host damage, respectively, during fungal encounters. Leukotrienes help regulate inflammatory responses against fungal infections.
View Article and Find Full Text PDFBiological Evaluation of Lysionotin: a Novel Inhibitor of 5-Lipoxygenase for Anti-glioma.
Chin J Integr Med
September 2024
Institute for Literature and Culture of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
Objective: To explore the potential mechanism of lysionotin in treating glioma.
Methods: First, target prediction based on Bernoulli Naïve Bayes profiling and pathway enrichment was used to predict the biological activity of lysionotin. The binding between 5-lipoxygenase (5-LO) and lysionotin was detected by surface plasmon resonance (SPR) and molecular docking, and the inhibitory effects of lysionotin on 5-LO and proliferation of glioma were determined using enzyme inhibition assay in vitro and cell viability analysis, respectively.
Single and multiple inhibitors of the biosynthesis of 5-, 12-, 15-lipoxygenase products derived from cinnamyl-3,4-dihydroxy-α-cyanocinnamate: Synthesis and structure-activity relationship.
Drug Dev Res
May 2024
Chemistry and Biochemistry Department, Université de Moncton, Moncton, New Brunswick, Canada.
The involvement of lipoxygenases in various pathologies, combined with the unavailability of safe and effective inhibitors of the biosynthesis of their products, is a source of inspiration for the development of new inhibitors. Based on a structural analysis of known inhibitors of lipoxygenase products biosynthesis, a comprehensive structure-activity study was carried out, which led to the discovery of several novel compounds (16a-c, 17a) demonstrating promising potency to inhibit the biosynthesis of products of 5-, 12- and 15-LO. Compounds 16b and 16c outperformed zileuton (1), the only FDA-approved 5-LO inhibitor, as well as known inhibitors such as caffeic acid phenethyl ester (CAPE (2)) and cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC (4)).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!